Ann: Direct Sale of APAS Independence in United States, page-65

For so long its been difficult to understand why our SP has continued to decline despite the all the progress made:

• Results from Johns Hopkins trial;
• MRSA (FDA) approval;
• Thermo Fisher announced as US Distributor;
• Sales to Sonic Healthcare (UK), Limbach Group (EU), Albany Medical (US);
• Additional 5 x recent sales (US) through Thermo Fisher; and
• Pipeline (AMR and other modules, Early Plate Reading, Industry Expansion etc.)

But the downtrend hasn't been isolated to just LBT... its been across all biotech/ healthcare - PNV, RAC, IMU, IBX, CUV, TLX etc. however there appears to be a shift, and the sector is showing strength.. many are breaking through their downtrend and/ or starting to move higher.

From a TA perspective, LBT has finally broken through the past 10 month downtrend resistance line. Hopefully that gives existing, and new potential investors greater confidence.


From a FA perspective - hopefully Thermo Fisher can continue driving sales in the US (the current high US dollar is good for revenue given sales are in USD), and the business can announce progress with sales in Europe, AMR and other module development, early plate reading, industry expansion etc